G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates

This article was originally published on Nasdaq

G1 Therapeutics (GTHX) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.94 per share a year ago. These figures are adjusted for non-recurring items.